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been no documented reports of the association between XPD-
Lys751Gln and nasopharyngeal carcinoma risk until now. The fre-
quency of the XRCC1 codon 280 homozygous wild-type Arg/Arg
genotype was 77.9% (88/113) in cases and 80.8% (105/130) in con-
trols; the heterozygous Arg/His genotype was 21.3% (24/113) in
cases and 18.5% (24/130) in controls; and the His/His genotype
was 0.8% (1/113) in cases and 0.7% (1/130) in controls. For XRCC1
codon 280 polymorphisms, no significant association between
Arg280His and risk of NPC was found (OR 1.30, 95% CI 0.66–2.57;
p = 0.447).
Interpretation: Risk of NPC was nearly two and a half times
higher for individuals with the homozygous wild-type Lys/Lys
genotype than for the heterozygous Lys/Gln genotype, adjusted
for age, sex, and ethnicity. To our knowledge, there have been
no documented reports of the association between XPDLys751Gln
and nasopharyngeal carcinoma risk until now.
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Background: We evaluated the safety and efficacy of nim-
otuzumab in combination with radiotherapy for oesophageal car-
cinoma (ESO).
Methods: 42 patients with stage II–IVa ESO were randomly
assigned as part of this prospective, phase 2 trial, fromNovember,
2008, to July, 2010. All patients received 50–70 Gy three-dimen-
sional conformal radiotherapy. 200 mg of nimotuzumab was
administered via intravenous infusion once a week during
radiotherapy.
Findings: Primary cancer lesions were located in the upper,
middle, and lower thoracic segments of the oesophagus in 10,
26, and 3 patients, respectively. Nine patients had stage II ESO,
25 had stage III, and eight had stage IVa. All patients received
50–70 Gy of radiation and 37 patients (88.1%) received nim-
otuzumab more than five times. Grade 3 toxicities were nausea
and vomiting (n = 1), oesophagitis (n = 3), skin reactions (n = 4),
and haematological toxicity (n = 1). One patient had an allergic
reaction to nimotuzumab. Four patients (9.5%) had a complete
response, 21 (50%) had a partial response, two (4.8%) had stable
disease, and 15 (35.7%) had progressive disease. The overall
disease control rate was 64.3%. With a median follow-up of 6
months, local recurrence was observed in six patients (14.3%)
and distance metastasis in ten (23.8%). Ten patients died, with
eight possible cancer-related deaths. The median survival time
has not yet been reached. 6-month and 1-year overall survival
rates were 82.4% and 57.8%.
Interpretation: Nimotuzumab in combination with radiother-
apy is well tolerated and effective for treatment of ESO. Long-term
toxicity and long-term efficacy require further evaluation.
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Background: Sentinel lymph node (SLN) mapping has recently
been introduced in the treatment of gastric cancer. Although
immunohistochemistry and conventional real-time PCR (RT-
qPCR) provide reliable information about micrometastases in
SLNs, they cannot examine large numbers of lymph nodes in a
short time, making them unfeasible for intraoperative use. The
SLN is defined as the first node to receive cancer-cell drainage
from the primary tumour, therefore micrometastases or isolated
tumour cells should first develop in these nodes. In this preli-
minary study, we evaluated the concept of single SLN screenings
for micrometastases by use of the Maruyama computer
program.
Methods: 23 patients were enrolled in our study: nine patients
were included in the control group and 14 in the study group. The
first stained lymph node was analysed with RT-qPCR for carcino-
embryonic antigen and CK-20 expression, as markers for microm-
etastases. Patients characteristics were retrospectively used as
predictors in the Maruyama computer program, to determine
the most likely metastatic site. Results were compared with the
actual staining patterns, and correlations between tumour char-
acteristics and micrometastases were examined.
Findings: 14 patients were found to be N0. Micrometastases
were detected in four patients (28.6%). In 76.9% of cases, extracted
SLNs coincided with lymph nodes predicted by the computer pro-
gram to be the most likely metastatic site. Micrometastases were
more common in Maruyama-predicted lymph nodes. Laurens
histological type distribution, preoperative CA 19-9 values, and
age distribution differed significantly between patients who were
positive and negative for micrometastases.
Interpretation: These results indicate the potential use of a sin-
gle SLN for intraoperative decision making; however, sensitivity
and specificity need to be evaluated in a larger series, supported
by long-term recurrence and survival results.
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Background: The advantages of proximal resection with jejunal
interposition and modified D2 lymphadenectomy, for elderly
patients, could outweigh the higher risk of recurrence with this
less radical lymphadenectomy. The aim of our study was to eval-
uate proximal resection with modified D2 lymphadenectomy as
an alternative in selected patients.
Methods: Between 1993 and 2009, 161 patients at our centre
had surgery for adenocarcinoma of the proximal third of the
stomach. Patients were divided into three groups: (1) PG, proximal
resection with jejunal interposition and modified D2 lymphade-
nectomy (19.3%, 31 patients); (2) TH, transhiatal extended total
gastrectomy with resection of the distal oesophagus and D2 lym-
phadenectomy (23.6%, 38 patients); (3) GT, total gastrectomy with
D2 lymphadenectomy (57.1%, 92 patients). We analysed postoper-
ative morbidity, 30-day mortality, and survival. Quality of life was
evaluated with the gastrointestinal quality-of-life index (GIQLI)
questionnaire.
Findings: Patients in the PG group (79.4 ± 9 years) were signifi-
cantly older than the patients in the GT (63.9 ± 11 years) or TH
group (60.1 ± 12 years; p < 0.0001), and in worse general condition.
Fewer lymph nodes were harvested in the PG group (17.2 ± 11)
than in the GT and TH groups (24.05 ± 13 and 26.3 ± 13). There
were no significant differences in the distribution of pathohisto-
logical characteristics and tumour TNM stages between groups.
An R0 resection could be done in 77.2–86.8% of cases. 30-day mor-
tality was 9.7% in the PG group, 6.5% in GT, and 5.3% in TH. There
were no differences in morbidity and 5-year survival between
groups (25.3% in PG, 26.3% in GT, and 28.9% in TH). No differences
were found in the total scores of the GIQLI questionnaire
(p = 0.893). Patients in the PG group had the lowest scores in diges-
tive functions.
Interpretation: Proximal resection should be reserved for high-
risk elderly patients with proximal gastric cancer, who have
shorter expected long-term survival. These resections carry
acceptable morbidity and mortality; however, reconstruction with
jejunal interposition does not bring the desired functional
benefits.
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Background: Chemotherapy-induced neutropenia, a toxic effect
of systemic chemotherapy, is often associated with substantial
mortality and morbidity; thus, identifying its related determi-
nants is necessary. The aim of this study was to identify the main
consequences of severe neutropenia following adjuvant chemo-
therapy, in a community-based population of patients with can-
cer in Iran-Semnan.
Methods: This prospective study included 828 consecutive
patients who received chemotherapy for histologically proven
primary or metastatic solid tumours. Demographics data, disease
characteristics, and comorbidities (including current smoking
and diabetes) were collected from interviews with the patients
and their laboratory data and files. Patients had a complete blood
count 1 week after the first course of chemotherapy.
Findings: Based on the absolute neutrophil count nadir value,
30 patients (3.6%) had severe neutropenia. Multivariable
logistic-regression analysis showed that advanced age (OR =
5.262, p = 0.012) and diabetes mellitus (OR = 8.126, p = 0.015) were
main determinants of severe neutropenia, with the presence
of demographic characteristics and comorbidities as
confounders.
Interpretation: We identified advanced age and diabetes as
main determinants of high-grade neutropenia in Iranian patients
with solid tumours who were receiving adjuvant chemotherapy.
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Background: Total thyroidectomy and central neck dissection
are the procedures of choice for patients with medullary thyroid
carcinoma (MTC). We reviewed patients with advanced MTC
who underwent surgical treatment, to discuss the clinical out-
comes and prognostic factors.
Methods: 132 patients had total or subtotal thyroidectomy with
central neck dissection. Ipsilateral (n = 96) and bilateral (n = 36)
modified radical neck dissection was done simultaneously, in
patients with and without evidence of suspicious lymph nodes.
After surgery, basal and stimulated serum calcitonins (Cts) were
measured in all patients. Follow-up ranged between 5 and 12.5
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